DGAP-News: Study reported in BMC Gastroenterology shows significantly better performance characteristics of Epigenomics' liver cancer panel compared to the current standard of care for the early detection of HCC
In addition, HCC is considered the second leading cause of cancer-related deaths world-wide with more than 780,000 deaths annually.
- In addition, HCC is considered the second leading cause of cancer-related deaths world-wide with more than 780,000 deaths annually.
- The study compared patients with cirrhosis who had early-stage treatable liver cancer with patients having cirrhosis but no cancer.
- The current standard of care for HCC surveillance is ultrasound plus AFP with a sensitivity of 63% and a specificity of 84%.
- Epigenomics AG is a molecular diagnostics company focused on blood testing for the early detection of cancer.